Bempedoic Acid
Cardiovascular Risk Reduction
Key Facts
About Esperion Therapeutics (2)
Esperion Therapeutics has successfully transitioned from a research entity to a commercial company with two FDA-approved products: NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe). Its strategy centers on maximizing the U.S. commercial potential of its oral, non-statin LDL-lowering franchise while leveraging international partnerships for global reach. The company's core achievement is establishing a new therapeutic class with a differentiated mechanism designed to avoid muscle-related side effects, targeting the vast population of patients with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH).
View full company profileAbout Esperion Therapeutics (2)
Esperion Therapeutics has successfully transitioned from a research entity to a commercial company with two FDA-approved products: NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe). Its strategy centers on maximizing the U.S. commercial potential of its oral, non-statin LDL-lowering franchise while leveraging international partnerships for global reach. The company's core achievement is establishing a new therapeutic class with a differentiated mechanism designed to avoid muscle-related side effects, targeting the vast population of patients with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH).
View full company profileAbout Esperion Therapeutics
Esperion Therapeutics' mission is to deliver oral, once-daily, non-statin medicines for patients with elevated LDL-C. Its key achievement is the successful FDA approval and commercialization of bempedoic acid (NEXLETOL) and its combination with ezetimibe (NEXLIZET), establishing a new therapeutic class. The company's strategy combines direct U.S. commercialization with ex-U.S. partnerships to maximize global reach while advancing a pipeline of next-generation lipid-modifying agents. Esperion aims to become a leading cardiometabolic company by addressing broader patient populations and complementary risk factors.
View full company profileTherapeutic Areas
Other Cardiovascular Risk Reduction Drugs
| Drug | Company | Phase |
|---|---|---|
| Vascepa (icosapent ethyl) | Ligand Pharmaceuticals | Marketed |
| BGE-102 | BioAge Labs | Phase 1b/2a |
| VASCEPA/VAZKEPA (Icosapent Ethyl) | Amarin Corporation | Approved |